<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970953</url>
  </required_header>
  <id_info>
    <org_study_id>21-9993-BO</org_study_id>
    <nct_id>NCT04970953</nct_id>
  </id_info>
  <brief_title>Diastolic Exercise Stress Testing in Heart Failure</brief_title>
  <acronym>DEST-HF</acronym>
  <official_title>Prospective Analysis of Diastolic Stress Tests to Detect Exercise Induced Heart Failure With Preserved Ejection Fraction (HFpEF) in Patients With Intermediate Risk (DEST-HF Study, Diastolic Exercise Stress Testing in Heart Failure)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with an intermediate risk (HFA-PEFF score 2-4 points) for heart failure with&#xD;
      preserved ejection fraction (HFpEF) will be further investigated with invasive right heart&#xD;
      catheterization. All patients with a resting pulmonary artery wedge pressure (PAWP) &lt;15mmHg&#xD;
      will undergo the following stress test modalities in a randomized order: (1) bicycle&#xD;
      ergometry, (2) dynamic handgrip exercise, (3) 500ml fluid challenge over 5 minutes, (4) leg&#xD;
      raise testing. Exercise induced HFpEF will be diagnosed if PAWP rises to &gt;25mmHg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients reporting to the investigators' clinic for in- and outpatient consultation and a&#xD;
      HFA-PEFF score of 2-4 points will be recruited if their dyspnea is not sufficiently explained&#xD;
      by other causes than HFpEF. Patients will undergo a baseline clinical exam, transthoracic&#xD;
      echocardiography with measurement of diastolic parameters, and ECG. NYHA class will be&#xD;
      reported, standard lab works (NTproBNP, GFR, CRP, Hb, PLT, blood gas analysis) will be taken.&#xD;
      The number of patients with a PAWP increase in right heart catheterization (brachial access&#xD;
      under sonographic guidance) from a resting value of &lt;15mmHg to &gt;25mmHg during stress testing&#xD;
      will be assessed across the four interventions. During bicycle ergometry (semi-supine&#xD;
      position) spiroergometric data and gas exchange variables (cardiopulmonary exercise testing)&#xD;
      will be co-assessed. Between the testing modalities a 10-minute break will allow hemodynamic&#xD;
      variables to normalize.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PAWP increase across the four stress tests</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients with an increase of PAWP&lt;15mmHg at rest to &gt;25mmHg during stress testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of mean pulmonary artery pressure (mPAP) across the four stress tests</measure>
    <time_frame>1 year</time_frame>
    <description>mPAP changes [mmHg] during stress testing will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of PAWP increase and changes of VO2peak during bicycle ergometry</measure>
    <time_frame>1 year</time_frame>
    <description>associations between PAWP [mmHg] and VO2peak [ml/kg/min] during bicycle ergometry will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of pulmonary vascular resistance (PVR) across the four stress tests</measure>
    <time_frame>1 year</time_frame>
    <description>PVR changes [WU, Wood Units] during stress testing will be assessed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Patients with intermediate risk for HFpEF at rest</arm_group_label>
    <description>Patients with a HFA-PEFF score of 2-4 points and no obvious extracardiac explanation for exercise-induced dyspnea. Right heart catheterization with be performed at rest and during stress testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Right heart catheterization</intervention_name>
    <description>Right heart catheterization will be performed via a brachial access under sonographic guidance and hemodynamic measurements will be performed in a semi-supine position.</description>
    <arm_group_label>Patients with intermediate risk for HFpEF at rest</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients reporting to the investigators' in- and outpatient clinic with unsolved dyspnea&#xD;
        through non-invasive testing and a HFA-PEFF score 2-4 points and thus an intermediate risk&#xD;
        for HFpEF. Following the diagnostic algorithm of HFpEF invasive stress testing is&#xD;
        indicated.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Unclear etiology of dyspnea with non-invasive testing&#xD;
&#xD;
          -  HFA-PEFF score 2-4 points and thus an intermediate risk for HFpEF&#xD;
&#xD;
          -  Willingness to participate and obtained written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consent for study participation not obtained&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Medical contraindications to perform right heart catheterization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Lüdike, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hopsital Duisburg-Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Lüdike, Professor</last_name>
    <phone>+49-201-72384809</phone>
    <email>peter.luedike@uk-essen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik für Kardiologie und Angiologie-Westdeutsches Herz- und Gefäßzentrum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Lüdike, Professor</last_name>
      <phone>+4920172384878</phone>
      <email>peter.luedike@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Simon Wernhart, Dr.Dr.</last_name>
      <phone>+491751830099</phone>
      <email>simon.wernhart@uk-essen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019 Oct 21;40(40):3297-3317. doi: 10.1093/eurheartj/ehz641. Erratum in: Eur Heart J. 2021 Mar 31;42(13):1274.</citation>
    <PMID>31504452</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Peter Lüdike</investigator_full_name>
    <investigator_title>Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>diastolic stress testing</keyword>
  <keyword>HFpEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

